Climate change is rapidly becoming one of the defining challenges for healthcare. While much of the pharmaceutical sector’s sustainability agenda has focused on reducing carbon emissions, improving resource efficiency and meeting ambitious net-zero commitments, an equally important issue is beginning to emerge: adapting medicines management to a changing climate.
As temperatures continue to rise, the industry’s long-established assumptions around medicines storage after dispensing warrant closer examination. The integrity of the pharmaceutical supply chain has always depended upon robust environmental controls, yet once medicines reach patients’ homes, those controls effectively cease.
This raises an important strategic question for manufacturers, regulators, healthcare providers and pharmacy professionals alike: are current approaches to medicines storage still fit for purpose in a warming climate?
The Final Stage of the Supply Chain Is Increasingly Vulnerable
Throughout manufacturing, distribution and pharmacy operations, temperature and humidity are rigorously monitored to ensure medicines remain within their licensed storage conditions. Significant investment has been made across the sector to strengthen cold chain logistics, improve warehouse monitoring and ensure Good Distribution Practice (GDP) compliance.
However, the final stage of the medicines journey—the patient’s home—remains largely unmanaged.
Historically, this has presented relatively little concern within the UK. Domestic environments were generally assumed to remain within acceptable storage limits for most medicines. However, that assumption is becoming increasingly difficult to justify.
Recent heatwaves have demonstrated that indoor temperatures can remain above recommended storage conditions for prolonged periods, with research indicating that more than half of UK homes now experience overheating during extreme weather events. As climate projections indicate that such events will become more frequent, medicines stored in domestic settings may increasingly be exposed to conditions beyond those anticipated during product licensing.
While not every medicine will be significantly affected, the issue introduces an emerging risk that deserves greater attention across the sector.
Climate Adaptation Must Extend Beyond Manufacturing
The pharmaceutical industry’s response to climate change has, understandably, prioritised mitigation. Organisations have invested heavily in decarbonising manufacturing, improving packaging sustainability and reducing emissions throughout global supply chains.
Adaptation, however, has received comparatively less attention.
Protecting medicine quality in a changing climate requires looking beyond operational resilience to consider how products perform throughout their entire lifecycle—including the period after dispensing.
Evidence from patient surveys suggests medicines continue to be commonly stored in kitchens and bathrooms, environments already associated with fluctuating humidity and temperature. As residential overheating becomes more widespread, even traditionally suitable storage locations may experience temperatures above recommended limits for extended periods.
This represents a challenge that existing medicines optimisation strategies have yet to fully address.
An Opportunity for Industry Leadership
The pharmaceutical sector has an opportunity to take a proactive approach before this becomes a more significant patient safety concern.
Manufacturers, regulators and healthcare providers could work collaboratively to strengthen guidance around domestic medicines storage. This may include reviewing patient information materials, evaluating whether current storage recommendations remain sufficiently robust under projected climate conditions, and exploring how seasonal messaging could be incorporated into routine patient communications.
There is also an opportunity to better understand real-world storage conditions. Advances in environmental monitoring, digital health technologies and real-world evidence could provide valuable insights into how medicines are actually stored across different housing types and climatic conditions, helping to inform future regulatory and product development strategies.
Pharmacy Has a Critical Role to Play
Pharmacy professionals remain uniquely positioned at the interface between medicines and patients.
Research consistently suggests that patients are willing to follow professional advice regarding medicines storage, yet relatively few report receiving routine guidance. This represents a missed opportunity for medicines optimisation.
Incorporating practical storage advice into routine consultations—particularly during periods of extreme heat—could become an increasingly valuable component of pharmaceutical care. Such interventions require minimal additional resource while supporting medicine quality, treatment effectiveness and patient confidence.
Looking Ahead
Climate resilience is rapidly becoming a strategic priority across healthcare. For the pharmaceutical industry, resilience should not end when a medicine leaves the distribution network.
As domestic environments become warmer, the assumptions underpinning long-standing storage guidance deserve renewed scrutiny. Ensuring medicines remain within appropriate environmental conditions throughout their full lifecycle will require collaboration between manufacturers, regulators, healthcare providers and pharmacy teams.
The conversation around climate change in pharmaceuticals is evolving. Alongside decarbonisation and sustainable manufacturing, adaptation must become part of the industry’s strategic agenda. The organisations that begin addressing these challenges today will be better positioned to safeguard medicine quality, strengthen patient outcomes and build resilience into pharmaceutical care for the decades ahead.